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The effect of the pituitary hormone prolactin on in vitro 
proliferation of human k~ratinocytes has be.e~ st~died. Cell 
proliferation was dete~mll:ed by [3H] thY~1lldu~e Incorpora-
tion and cell enumeratIOn In culture. PhysIOlogIC concentra-
tions of prolactin ma~kedly stir~lUlated proliferation. of new-
born foreskin keratInocytes In serum-free medmm. In 
addition, it was able to replace almost completely the 
growth-promoting effects of bovine pituitary extract, a com-
monly added supl?leme~t for keratinocyte c~lture. This ac-
tivity was also eVident In the absence of epidermal growth 
T he growth of normal human keratinocytes in vitro is under the control of several hormonal factors. Serum-free culture of normal human keratinocytes has dem-onstrated that epidermal growth factor (EGF), insu-lin, and hydrocortisone are required for optimal 
proliferation [1- 4]. Insulin-like growth factor 1, a liver-derived 
factor has also been reported to promote proliferation of human 
kerati~ocytes, although in the same study growth hormone, which 
is derived from pituitary, did not [5] . In fact, bovine pituitary extract 
(BPE), has been employed .extensively f?r its .capacity to promote 
keratinocyte growth; BPE 1I1creases prolIferatIOn and prolongs the 
life span of cells in culture [3,4] . The pituitary gland produces an 
array of hormones that may be potentially involved in these effects, 
yet our knowledge of these factors remain.s inc?~plete [6,7] 
Prolactin [PRLj, a product of the antenor pitUItary gland, pos-
sesses a variety of physiologic actions [8]. Its growth-promoting 
activity in vivo is well established for several target organs, such as 
mammary gland, prostate, seminal vesicles, and liver [9,10], and the 
proliferative response of pigeon crop-sac mucosal epithelium has 
been used classically as a biologic assay for this hormone [9]. In vitro, 
PRL stimulates the growth of normal as well as malignant mam-
mary epithelial cells [11-13], renal epithelial cells [14], lym-
phocytes [15,16], thymic epithelial cells [17], and GH3 pituitary 
cells [18]. 
In this study, we investigated the effects of PRL on human 
keratinocytes cultured under defined serum-free conditions. We 
show that PRL exerts a proliferative effect on keratinocytes in cul-
ture as determined by cell number and [3H]thymidine incorpora-
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factor, but required the presence of insulin. Radioligand-
binding studies confirmed the expression of specific prolactin 
binding sites (Kd 8.9 nM; 1350 sites per cell) on freshly 
procured keratinocyte membranes. These results extend its 
hormonal influences to include regulation of in vitro prolifer-
ation of human keratinocytes, and suggest the possibility of a 
completely defined growth medium for keratinocytes. Key 
words: epidermis/pituitary hormones/serum-free culture/ 
receptors.] Invest DermatoI101 :275-279, 1993 
tion. ~ad!oligand-binding studies identify specific, high-affinity 
PRL ~1l1dmg sites on membrane preparations from freshly isolated 
kera~1l1ocytes. These results indicate that human keratinocytes have 
spe~lfic .PRL recept~rs and that it markedly stimulates their prolif-
eratIOn 111 culture With an activity comparable to that of BPE. 
MATERIALS AND METHODS 
Primary Cell Cultures Primary culrures were established from newborn 
foreskins. S.mall skin fragments were floated in 0.5% dispase (neutral pro-
tease; Bohnnger Mannhelm) for 3 h at 37"C, and the separated epidermis 
was placed into 0.3% trypsin (Type Xl; Sigma) for 10 min at 37°C. Disag-
gregated epidermal cells were filtered, washed, and then culrured according 
to Green et af [19]. Briefly, epidermal cells were seeded in 75-cm2 culrure 
flasks at 10-15 X 10'/cm2 on a feeder layer of mitomycin-treated (4 Jlg/ml 
for 2 h; Sigma) 3T3/J2 cells and then cultured in Dulbecco's modified 
Eagle's medium/Ham's F12 medium (3: 1) (GIBCO), containing mouse 
EGF (10 ng/ml; Sigma), cholera toxin (0.1 nM; Sigma), hydrocortisone (0.4 
Jlg/ml; Calbiochem), transferrin (5 Jlg/ml; Sigma), adenine (18 tlM; Sigma) , 
triiodothyronine (2 nM; Sigma), 1% penicillin-streptomycin (GIBCO), 
and 10% fetal bovine serum (Hyclone) . 
Alternatively, primary culrures were established in serum-free conditions 
[supplemented keratinocyte basal medium (KBM)] [4] . Cells were seeded 
(3-4 X 104/cm2) ina high amino acid formulationofMCDB 153 with 0.15 
mM CaCl2 (KBM; Clonetics), supplemented with 10 ng/ml mouse EGF, 
0.4 Jlg(ml hydrocortlson~, S Jlg/ ml bovine insulin, 70 Jlg/ ml BPE (all 
Clonetlcs), and 1% pemcllhn-streptomycin (GIBCO). At 70 - 80% con-
fl~ence, keratino~ytes.were detached with a 0.1 % trypsin/0.02% ethylene-
dlanune tetraacetlc aCid (EDTA) solution and, if not used for experimental 
procedures, subcultivated with supplemented KBM. 
Cell Proliferation Assay Recently prepared keratinocytes (first through 
third passages) were subcultured in duplicate in 1.9 cm2 wells at 5 -1 0 X 10' 
cells/cm2 in supplemented KBM at 37"C with 5% CO2, After 2-16 h, this 
medium was . rc:placed with fresh KBM (with or without added growth 
factors) contammg mcreasmg concentrations of human or rat PRL [National 
Hormone and Piruitary Program, National Institutes of Health, Bethesda, 
MD (NIH)]. Medium was changed every 2 to 3 d. After 3 - 8 d, cells were 
detached, collected, and counted using a hemocytometer. Parallel culrures 
were fixed f~r 30 min with 4% fonnaldeh. yde in phosphate-buffered saline, 
and then stamed With 1% crystal VIOlet m methanol for 3 min [20]. 
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Thymidine Incorporation Assay For this assay, 5-7 X 103 kcratino-
cytes per well were plated in quintuplicate in flat-bottom 96-well plates in 
0.2 ml of supplemented KBM at 37"C with 5% CO2. After 2-16 h, this 
medium was replaced with the experimental medium, which was changed 
every other day. After 4 - 6 d (70 - 80% con fluency for the most proliferating 
cultures) [3H]thymidine (1 J.LCi/well, 6.7 Ci/mM; ICN Radiochemicals) 
was added. Sixteen to twenty-four hours later, cells were detached, harvested 
with an automatic cell harvester, and analyzed in a liquid scintillation 
counter. 
PRL Receptor Binding Assay One hundred million to two hundred 
million viable keratinocytes were obtained from keratomized skin from 
recently deceased human cadavers « 24 h from time of death), ranging in 
age from 18 to 34 years (Transplant Services Center, University of Texas 
Southwestern Medical Center, Dallas). Human foreskin keratinocytes could 
not be used in these binding studies owing to insufficient availability. 
Briefly, epidermis was separated from dermis with 0.5% dispase for 60 min 
at 37 ' C, and then placed into 0.3% trypsin for 20 min at 37'C. Cell suspen-
sions were filtered through Sera-Sepra columns (Evergreen) and washed in 
Hanks' balanced salt solution (GIBCO) containing 1 mM N-2-hydroxyeth-
ylpiperazine-N/-2-ethanesulfonic acid (Sigma). In some experiments, sin-
gle-cell keratinocyte suspensions were stripped of any pre-bound PRL by 
exposure to 0.1 % acetic acid in 0.15 M NaC1j0.1 % bovine serum albumin 
(BSA), pH 4.0, for 3 min at 4' C. Crude membranes were prepared by 
sonicating keratinocyte cell suspensions in Dulbecco's phosphate-buffered 
saline containing 0.4 mM phenylmethylsulfonylfluoride (Sigma) as a pro-
tease inhibitor. Membrane fragments were pelleted at 10,000 X g for 5 min, 
washed in DPBS containing 0.4 mM phenylmethylsulfonylfluoride and 
0.1 % BSA, and finally suspended in the same balanced salt solution, pH 7.4. 
Human PRL (molecular weight 23,000) from the National Hormone and 
Pituitary Program (NIH) was used for iodination and all competitive bind-
ing inhibition studies. Iodination using the iodogen method [21] yielded 
specific activities of 50-60 mCi/mg. Equilibrium-binding studies were 
performed using triplicate samples of keratoinocyte membranes from 1.4 
million cells each, incubated with 4 ng 1251_PRL and varying amounts of 
unlabeled P):tL at room temperature for 60 min in a total volume of 0.125 
m!. Previous studies established saturable equilibrium binding under these 
conditions in 50 min (data not shown). Binding was terminated by layering 
the reaction mixture over ice-cold 1 % BSA-DPBS and centrifuging at 
10,000 X g for 3 min at 4'C. Bound 12sI_PRL was determined by counting 
cut polypropylene centrifuge tube tips containing the washed membrane 
pellets in a Packard gamma counter. Non-specific binding was determined 
in the presence of a hundredfold molar excess of unlabeled PRL. Binding 
data were analyzed by non-linear curvefit software (EBDA/LIGAND; Bio-
Soft) [22]. Equilibrium binding studies using radioiodinated rat PRL with 
unlabeled human PRL yielded similar results (data not shown). 
RESULTS 
Cell Proliferation Rat or human PRL stimulated proliferation 
ofkeratinocytes, each with differing dose-response curves. Rat PRL 
induced a concentration-dependent increase in both [3H)thymidine 
incorporation and cell number, with maximal activity at 50-100 
ng/ml (Fig 1). By contrast, the growth-stimulating effect of human 
PRL increased between 0.001 and 10 ng/ml (102 -105 times more 
potent than rat PRL), with no additional effect at higher concentra-
tions (Figs 2 and 3) . [3H)thymidine uptake and the increase in cell 
numbers produced parallel results. In some experiments PRL con-
centrations higher than 10 ng/ml resulted in reduced stimulation. 
Both rat and human PRL showed a maximum potency similar to 
BPE in their mitogenic activity. 
Human PRL was also able to induce keratinocyte proliferation in 
the absence of EGF, although its maximal effect was shifted to 
higher concentrations (Figs 2-4). The stimulating activity of 
human PRL was also evident, albeit greatly reduced, after the addi-
tional removal of hydrocortisone (data not shown). Finally, the 
elimination of insulin, together with EGF and hydrocortisone, re-
sulted in complete loss of PRL-stimulating activity (Fig 5); how-
ever, BPE was still able to promote DNA synthesis under these 
conditions. Assay of specific PRL bioactivity [16) in BPE (same 
batch used in proliferation experiments) indicated 1.6 ng PRL per 
microgram of BPE (data not shown). Therefore, at a final culture 
BPE concentration of 70 ,ug/mJ, the bioactive PRL concentration 
was estimated to be approximately 110 ng/ml. 
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Figure 1. Dose-dependent stimulation of keratinocyte proliferation by rat 
PRL, evaluated by [3HJthymidine incorporation (A) or cell number (B). 
Keratinocytes were cultured in KBM supplemented with 10 ng/ml EGF, 0.4 
Jlg/ml hydrocortisone, and 5 J.Lg/ml insulin (0), and with added BPE (II) (70 
Jlg/ml) or increasing concentrations of rat PRL (e). Cells were cultured in 
96-well plates for 4-6 d, pulsed with [3H]thymidine (1 J.Lei/well), and 
harvested after 16 - 24 h. 
PRL Receptor Binding Human keratinocytes express one class 
of specific saturable binding sites for PRL as determined by equilib-
rium binding analysis (Fig 6). The estimated Kd of these sites is 8.9 
nM, with an associated binding-site density of approximately 1350 
sites per cell. 
DISCUSSION 
Prolactin belongs to the growth-hormone family of cytokines, all of 
which have the capacity to regulate cell growth [8,23) . Indeed, PRL 
has been demonstrated to stimulate proliferation of epithelial cells 
from several sources, including normal and neoplastic mammary 
epithelium [11-13), liver [10), renal tubules [14), thymus [17), and 
pituitary mammary gland [18). 
Results from our study demonstrate that PRL is a potent growth 
factor for keratinocytes, with activity detected in the range of 0.001 
to 10 ng/ml. Somewhat reduced stimulatory activity at higher con-
centrations may be related to receptor down-regulation, as has been 
observed in studies with breast cancer cells [13,24). This potency is 
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Figure 2. Dose-dependent stimulation of [3H]thymidine incorporation in \ 
kcratinocytes by human PRL. Cells were cultured in KBM containing 0.4 
J.Lg/ml hydrocortisone and 5 J.Lg/ml insulin. Added growth factors included 
70 jig/ml BPE, 10 ng/ml EGF, and/or human PRL in the following combi-
nations: (6) no added growth factors; (0) added EGF alone; (.t.) added BPE 
alone; (II) added EGF and BPE; (0) increasing concentrations of human PRL 
alone; (e) EGF and increasing concentrations of human PRL. 
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Figure 3. Numbers (± SEM) Df keratinDcytes after 3 d (A) Dr 7 d (B) Df 
culture. Black bars, media with EGF; hatched bars, media withDut EGF. PRL 
, (1 ng/ml) induced cell prDliferatiDn to an extent cDmparable to' BPE (70 
,ug/ ml). In media wlthDut EGF, Its actiVity was reduced but stdl eVident, 
cDmpared to BPE. Cu ltures were cDnducted in duplicate. 
comparable to that of whole BPE, and it is maintained even in the 
absence of EG F and hydrocortisone. By contrast, insu lin is required 
for the activity ofPRL, because in its absence all stimulating proper-
ties of PRL are lost. These observations parallel reports that BPE 
also requires insulin to sustain full clonal growth ofkeratinocytes [4) 
and that insulin is obligatory for the mitogenic activity of PRL in 
organ cultures of mouse mammar'y tissue [25). 
Bovine pituitary extract contains several factors that promote 
keratinocyte proliferation, including basic fibroblast growth factor, 
insulin-like growth factors, and EGF [6,7,26 - 28), indicating a pos-
sible role for several pituitary hormones in the control of keratino-
cyte growth . Prolactin, also produced by the anterior pituitary 
gland, may be an important growth-promoting compone~t ofB~E . 
Interestingly, we have shown BPE, as expected, to contain slgmfi-
A B C 
Figure 4. PhDtDgraph shDwing cultures Df keratinDcytes in 1.9 cm2 wells 
after 3 d Df culture in media deprived Df EGF: A, plus BPE 70 ,ug/ ml; B, 
without BPE; C, withDut BPE but in the presence Df 10 ng/ ml Df human 
PRL, respectively. Cells were fixed with 4% forma ldehyde and then stained 
with crystal viDlet 1 % in methanDI. 
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Figure .5. Pituitary hDrmDne prolactin requires insulin to' stimulate grDwth 
Df keratmDcytes. Cells were cultured in KBM alDne (A) Dr in KBM supple-
mented With 5 ,ug/ ml Df I11sulin (B). Neither EGF nDr hydrocDrtisDne were 
present. Human PRL stimulated DNA synthesis Dnly in the presence Df 
I11su lm. By cDntrast, the activity Df BPE was present, althDugh markedly 
reduced, also. in KBM alDne. 
cant amounts of bioactive PRL. The estimated PRL concentration 
con~ributed by BP~ in our studies closely approximates the mito-
ge11lc effect of Similar final concentrations of added PRL in the 
absence of BPE. 
Several molecules have been described that show extensive se-
quence homology to mammalian PRL and , like PRL, promote cell 
prohferatlon In an autocrine (and possibly paracrine and endocrine) 
manner. Th~se ~olecules inclu~e I?lacentallacto~en [29], proliferin 
[30,31), prohfenn-related protel11 l32) and PRL-hke protein A [30) . 
These protell1s are produced by several cell types, but especially by 
the placenta [33 ,34) . Indeed, placental extracts are known to be 
highly mito.genic fo~ cultured human keratinocytes [20,26]. All of 
these PRL-hke proteins are known to bind to the PRL receptor, and 
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Figure 6. Ligand analysis Df '2sI_rat PRL equilibrium binding to. human 
keratl11Dcytes crude membranes cDmpeted against unlabeled human 
PRL. B/ F ratios are represented X 103• Computer-fit binding parameter 
were estimated as Kll = 1.12E + 8 ± 1.07E + 7, R1 = 2.55E - 11 ± 
1.76E - 12, and Nl = O. Data and figure are representative of four experi-
ments. 
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may therefore have similar effects on the PRL receptor-bearing 
target tissue. These observations suggest several sources of PRL or 
PRL-related proteins, in addition to the pituitary gland. Interest-
ingly, PRL immunoreactivity has been recently detected in human 
eccrine sweat glands [35]; thus, a local origin of PRL within skin 
remains an attractive hypothesis. 
Radioligand-binding studies indicate that freshly procured 
human epidermal cells possess a single class of specific binding sites 
for PRL. The affinity (K.t = 8.9 nM) and the number ofpRL bind-
ing sites on freshly obtained keratinocytes are comparable to the 
affinity and the number of receptors rerorted previously for normal 
and neoplastic breast cell lines [36,37 . 
Studies in animals have demonstrated that PRL receptors are ex-
pressed in many tissues [38] , and PRL receptor mRNA has been 
identified in rat skin [39]. The strong degree of sequence identity in 
the extracellular portion between rat and human PRL receptors [40] 
suggests that rat PRL binds to human epidermal cells and promotes 
their growth via the same receptor. A relevant role for PRL in the 
regulation of cell proliferation is also suggested by the striking 
structural homologies among the PRL receptor and other growth 
factor receptors. This growth factor receptor family now includes, 
in addition to growth hormone and PRL receptors, the receptors for 
erythropoietin, interleukin-2, -3, -4, -6, and -7, and granulocyte-
macrophage colony-stimulating factor [41 - 43]. 
Physiologic serum levels of prolactin are approximately 5 - 20 
ng/ml, and the ability ofPRL to stimulate proliferation ofkeratino-
cytes at similar concentrations may be relevant in hyperproliferative 
conditions of the epidermis, such as psoriasis. Cyclosporine A exerts 
a cytostatic effect on keratinocytes both in vitro and in vivo, and it has 
been proved to be an effective treatment of psoriasis [44] . Among its 
many actions, cyclosporine A has been shown to inhibit PRL bind-
ing to the PRL receptor [45]. Recent experiments indicate that 
cyclosporine A reversibly decreases the affinity of the PRL receptor 
in whole cells and membrane fragments (Phillips JT; manuscript in 
preparation). Cyclosporine A also selectively inhibits the PRL-stim-
ulated increase in ornithine decarboxylase activity in many tissues 
[46], suggesting that the antiproliferative effects of this drug may be 
mediated, at least in part, by its ability to antagonize PRL. 
Thus, our results show that PRL is a growth factor for normal 
human keratinocytes in culture. The relevance of these findings in 
both physiologic and pathologic conditions is under active investi-
gation. 
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ANNOUNCEMENT 
The National Institute on Drug Abuse (NIDA) has an interest in research on the utility of hair 
as a specimen for the detection of drugs of abuse. The goals of this program are to encourage 
systematic research on the use of hair testing to detect drugs of abuse in an accurate and reliable 
manner, and to develop the necessary procedures and safeguards. Specific areas of interest are: 
pharmacological studies; analytical studies; and cost/benefit ratio analyses. Further information 
may be obtained from Rao S. Rapaka, Ph.D., or M. Beth Grigson Babecki, M.A., Division of 
Basic Research, National Institute on Drug Abuse, 5600 Fishers Lane, Rm. 10A-31, Rockville, 
MD 20857, (301) 443-6975. 
